Tuesday, July 08, 2025 9:18:14 AM
CTXR is possibly a short squeeze opportunity. It would be nice to know the real-time short numbers.
If anyone has live shorting data, that would be helpful. NASDAQ data is always old -- the next report coming out July 10 will be "as of" June 30.
Shorts got burned a little on this current run up. Maybe not BURNED, but certainly SINGED.
If anyone has live shorting data, that would be helpful. NASDAQ data is always old -- the next report coming out July 10 will be "as of" June 30.
Shorts got burned a little on this current run up. Maybe not BURNED, but certainly SINGED.
Recent CTXR News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/06/2026 08:15:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 08:32:33 PM
- Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development • PR Newswire (US) • 03/31/2026 01:11:00 PM
- Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts • PR Newswire (US) • 03/24/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/10/2026 01:03:55 PM
- Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers • PR Newswire (US) • 03/10/2026 12:47:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 02:25:21 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 02/24/2026 01:04:14 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/24/2026 01:02:12 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/24/2026 01:00:41 PM
- Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program • PR Newswire (US) • 02/24/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2026 01:30:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2026 01:00:57 PM
- Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ • PR Newswire (US) • 02/13/2026 01:00:00 PM
- Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ • PR Newswire (US) • 02/13/2026 01:00:00 PM
- Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar • PR Newswire (US) • 02/11/2026 01:00:00 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 01/28/2026 09:30:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/23/2025 09:49:06 PM
- Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update • PR Newswire (US) • 12/23/2025 09:30:00 PM
- Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update • PR Newswire (US) • 12/23/2025 09:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/23/2025 09:21:08 PM
- Citius Oncology Shares Sink After Announcing $18M Fundraising Deal • IH Market News • 12/09/2025 03:19:37 PM
- Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules • PR Newswire (US) • 12/09/2025 01:30:00 PM
